Search clinical trials for: KW-6356

Total 196 results

Virginia Commonwealth University
Vical

Withdrawn

Safety, Tolerability, and Immunogenicity of a Cytomegalovirus DNA Vaccine (CM04-101)

Congenital Cytomegalovirus Infection
Erchonia Corporation

Terminated

An Evaluation of the Effect of Low Level Laser Therapy on Diabetic Peripheral Neuropathy Pain

Diabetic Peripheral Neuropathy

United States
Erchonia Corporation

Completed

A Study to Evaluate the Effect of Low Level Laser Light on Low Back Pain

Low Back Pain

United States
Kyowa Kirin Co., Ltd.
Kyowa Hakko Kirin Pharma, Inc.

Completed

Study of KW-0761 (Mogamulizumab) in Subjects With Previously Treated Peripheral T-cell Lymphoma (PTCL)

Peripheral T-Cell Lymphoma

France, United Kingdom, Netherlands, Denmark, Italy, Spain
NovaCardia, Inc.
Merck Sharp & Dohme LLC

Completed

Dose Escalation Study of KW-3902 on Diuresis in Subjects With Congestive Heart Failure (CHF).

Heart Failure, Congestive

United States
Conatus Pharmaceuticals Inc.
Idun Pharmaceuticals

Completed

Safety and Efficacy Study of a Caspase Inhibitor in Patients Undergoing Liver Transplantation

Liver Transplantation | Hepatitis | Carcinoma, Hepatocellular | Cholestasis

United States, Germany
NovaCardia, Inc.
Merck Sharp & Dohme LLC

Completed

Effect of KW-3902IV in Combination With IV Furosemide on Renal Function in Subjects With CHF and Renal Impairment

Renal Insufficiency | Heart Failure, Congestive

United States
Conatus Pharmaceuticals Inc.

Completed

A Study of IDN-6556 in Cirrhotic Subjects With Portal Hypertension (PH)

Liver Cirrhosis | Portal Hypertension | Hepatic Cirrhosis

United States
Conatus Pharmaceuticals Inc.

Completed

Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis (ENCORE-NF)

Liver Diseases | Fibrosis | Non-alcoholic Steatohepatitis

United States, Spain, Germany
Kyowa Kirin Co., Ltd.

Completed

Placebo-Controlled Double-Blind Crossover Comparative Study of KW-6500 (6500-004)

Parkinson's Disease

Japan
Conatus Pharmaceuticals Inc.

Terminated

Pharmacokinetic and Pharmacodynamic Study of IDN-6556 in ACLF

Liver Cirrhosis | Acute on Chronic Hepatic Failure | Acute Liver Failure | Acute Alcoholic Hepatitis

United States, United Kingdom
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma

Sezary Syndrome | Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8 | Stage II Mycosis Fungoides and Sezary Syndrome AJCC v8 | Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v8 | Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8 | Transformed Mycosis Fungoides | Folliculotropic... and other conditions

United States
Emory University
National Cancer Institute (NCI)

Recruiting

Mogamulizumab and Extracorporeal Photopheresis for the Treatment of Sezary Syndrome or Mycosis Fungoides

Mycosis Fungoides | Sezary Syndrome | Primary Cutaneous T-Cell Non-Hodgkin Lymphoma

United States
Boehringer Ingelheim

Completed

Bioavailability of BI 1356 After Single Oral Administration Given as Different Tablet Formulation in Healthy Male Volunteers

Healthy
Kyowa Kirin Co., Ltd.

Terminated

A Study of KW-0761 in Subjects With HTLV-1 Associated Myelopathy (HAM)

HTLV-1 Associated Myelopathy

Japan
Conatus Pharmaceuticals Inc.

Completed

A Study of IDN-6556 in Subjects With Liver Cirrhosis (LC)

Liver Cirrhosis | Hepatic Cirrhosis

United States
Erchonia Corporation

Completed

Study of Low Level Laser Therapy to Treat Diabetic Peripheral Neuropathy Foot Pain

Diabetic Peripheral Neuropathy

United States, Ireland
Conatus Pharmaceuticals Inc.

Completed

A Trial of IDN-6556 in Post Orthotopic Liver Transplant for Chronic HCV (POLT-HCV-SVR)

Liver Cirrhosis | Hepatic Fibrosis | Liver Fibrosis | Hepatic Cirrhosis

United States
Conatus Pharmaceuticals Inc.

Completed

A Study of IDN-6556 in Subjects With NAFLD and Raised Transaminases (NAFLD)

Non-alcoholic Fatty Liver Disease | Nonalcoholic Steatohepatitis

United States
Boehringer Ingelheim

Completed

BI 1356 BS in Japanese Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2
National Cancer Institute (NCI)

Completed

Mogamulizumab and Pembrolizumab in Treating Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent High Grade B-Cell Lymphoma | Refractory High Grade B-Cell Lymphoma | Recurrent Transformed B-Cell Non-Hodgkin Lymphoma | Refractory Transformed B-Cell Non-Hodgkin Lymphoma

United States
NovaCardia, Inc.
Merck Sharp & Dohme LLC

Completed

Placebo-Controlled Randomized Study of KW-3902 for Subjects Hospitalized With Worsening Renal Function and Heart Failure Requiring IV Therapy (REACH UP)

Heart Failure, Congestive
Kyowa Kirin Co., Ltd.

Completed

A Drug Interaction Study of KW-6356 and Clarithromycin or Rifampicin

Parkinson's Disease

Japan
Boehringer Ingelheim

Completed

Safety and Efficacy of Linagliptin (BI 1356) Plus Metformin in Type 2 Diabetes, Factorial Design

Diabetes Mellitus, Type 2

Canada, Croatia, Estonia, France, Germany, India, Lithuania, Mexico, Netherlands, Romania, Russian Federation, Sweden, Tunisia, Ukraine
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 1356 BS as Tablet in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2
Concert Pharmaceuticals

Completed

Healthy Volunteer Solid Oral Dose and Multiple Ascending Dose Evaluation of CTP-656

Healthy

Australia
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Immunogenicity of an HIV-1 gp41 MPER-656 Liposome Vaccine in Healthy, HIV-uninfected Adult Participants

HIV Infections

United States
Boehringer Ingelheim

Completed

Efficacy and Safety of 3 Doses of BI1356 (Linagliptin) in Type 2 Diabetes Patients

Diabetes Mellitus, Type 2

United States, Australia, Canada, Czech Republic, Russian Federation, Ukraine
Kyowa Kirin Co., Ltd.
Kyowa Hakko Kirin Pharma, Inc.

Terminated

Safety, Tolerability, and Efficacy Study in Subjects With Advanced or Metastatic Breast Cancer

Breast Cancer

United States
Syndax Pharmaceuticals

Completed

A Phase 1 Study to Investigate Axatilimab Alone or in Combination With Durvalumab in Patients With Solid Tumors

Solid Tumor | Unresectable Malignant Neoplasm | Locally Advanced Malignant Neoplasm | Metastatic Tumor

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
AstraZeneca; Syndax Pharmaceuticals

Completed

Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma

Unresectable Intrahepatic Cholangiocarcinoma

United States
Bayer

Completed

Non-interventional Multi-center Study on Patients Under Routine Treatment of Pulmonary Arterial Hypertension (PAH) With Inhaled Iloprost Using I-Neb as a Device for Inhalation (COMPHI)

Pulmonary Hypertension

Portugal
Kyowa Kirin Co., Ltd.

Completed

A Drug Interaction Study of KW-6356 With Midazolam, Caffeine, or Rosuvastatin

Parkinson's Disease

Japan
Kyowa Kirin Co., Ltd.

Completed

Multicenter, Randomized, Open-label, Parallel-group Study to Compare mLSG15 + KW-0761 to mLSG15

Adult T-cell Leukemia-Lymphoma

Japan
Conatus Pharmaceuticals Inc.

Unknown

Emricasan, a Caspase Inhibitor, for Treatment of Subjects With Decompensated NASH Cirrhosis (ENCORE-LF)

Decompensated Cirrhosis

United States
Osaka University
Ono Pharmaceutical Co. Ltd; Kyowa Kirin Co., Ltd.; Clinical Study Support, Inc.; Fiverings Co., Ltd...

Completed

Study of Pre-operative Combination Therapy With Mogamulizumab and Nivolumab Against Solid Cancer Patients

Gastric Cancer | Esophageal Cancer | Lung Cancer | Renal Cancer | Oral Cancer

Japan
Boehringer Ingelheim

Completed

Bioavailability of BI 1356 and Glyburide in Healthy Male and Female Volunteers

Healthy
Boehringer Ingelheim

Completed

Bioavailability of BI 1356 With and Without Co-administration of Pioglitazone and the Bioavailability of Pioglitazone With and Without Coadministration of BI 1356 in Healthy Male and Female Volunteers

Healthy
Boehringer Ingelheim

Completed

Bioavailability of Combination Tablet BI 1356/Metformin Compared With Single BI 1356 and Metformin Administered Together to Healthy Male and Female Subjects

Healthy
Boehringer Ingelheim

Completed

Pharmacokinetics and Pharmacodynamics of Multiple 5 mg Doses of BI 1356 p.o. Given Once Daily Compared to Multiple 2.5 mg Doses Given Twice Daily in Healthy Male and Female Volunteers

Healthy
NovaCardia, Inc.
Merck Sharp & Dohme LLC

Completed

PROTECT-1: A Study of the Selective A1 Adenosine Receptor Antagonist KW-3902 for Patients Hospitalized With Acute HF and Volume Overload to Assess Treatment Effect on Congestion and Renal Function

Heart Failure, Congestive
NovaCardia, Inc.
Merck Sharp & Dohme LLC

Completed

PROTECT-2: A Study of the Selective A1 Adenosine Receptor Antagonist KW-3902 for Patients Hospitalized With Acute HF and Volume Overload to Assess Treatment Effect on Congestion and Renal Function

Heart Failure, Congestive
Haukeland University Hospital

Completed

Hypertonic Saline-hetastarch in Cardiac Surgery (HH)

Postoperative Cardiorespiratory Failure

Norway
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Doses of BI 1356 BS in Healthy Male Volunteers

Healthy
Kyowa Kirin, Inc.

Completed

Study of Mogamulizumab + Docetaxel in Subjects With Non-small Cell Lung Cancer

Non-Small Cell Lung Cancer

United States
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising Oral Doses and Multiple Rising Oral Doses of BI 1356 BS in Healthy Male Volunteers

Healthy
Kyowa Kirin, Inc.
Bristol-Myers Squibb

Completed

Study of Mogamulizumab + Nivolumab in Subjects w/Locally Advanced or Metastatic Solid Tumors

Carcinoma | HCC | Cancer | Hepatocellular Carcinoma | Solid Tumor

United States
Kyowa Kirin Co., Ltd.
Ono Pharmaceutical Co. Ltd

Completed

Study of Combination Therapy With Mogamulizumab (KW-0761) and Nivolumab (ONO-4538/BMS-936558) in Subjects With Advanced Solid Tumors

Solid Tumor

Japan
Repare Therapeutics

Active, not recruiting

Study of RP-6306 With Gemcitabine in Advanced Solid Tumors

Adult Solid Tumor

United States, Canada, United Kingdom
be Medical

Terminated

Endovascular Treatment of Peripheral Artery Disease (PAD)

Peripheral Arterial Disease | Iliac Artery Disease | Femoropopliteal Occlusive Disease | Below-the-knee Obstruction

Belgium

Search clinical trials for: KW-6356

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Netherlands

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations